SCHEMBL4300243

SCHEMBL4300243

CN(C(=O)O)c1cc2cc(Br)ccc2cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCEH1 Q6PIU2 3/20 0.41
ABL1 P00519 1/20 0.39
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 2/20 0.38
GSK3A P49840 1/20 0.37
CDK9 P50750 1/20 0.37
CDK5 Q00535 1/20 0.37
TAOK1 Q7L7X3 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
LMNA P02545 2/20 0.36
GBA1 P04062 1/20 0.36
EGFR P00533 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MCL1 Q07820 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
KMO O15229 1/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295593 0.81 NCEH1 (0.42) NCEH1ABL1GSK3ACDK9CDK5
SCHEMBL2099047 0.80 GBA1 (0.50) ALDH1A1KDM4EGBA1EGFRSMN1; SMN2
SCHEMBL3475222 0.76 ALDH1A1 (0.50) NCEH1ALDH1A1KDM4ELMNASMN1; SMN2
SCHEMBL4072980 0.75 BACE1 (0.43) NCEH1ALDH1A1KDM4ELMNAEGFR
SCHEMBL29134506 0.73 NCEH1 (0.40) NCEH1ABL1GSK3ACDK9CDK5
SCHEMBL30015947 0.73 NCEH1 (0.40) NCEH1ABL1GSK3ACDK9CDK5
SCHEMBL4303492 0.73 LIPG (0.36) GSK3A
SCHEMBL30481293 0.72 KDM4E (0.56) ABL1ALDH1A1KDM4EGSK3ACDK9
SCHEMBL14684656 0.72 KDM4E (0.56) ABL1ALDH1A1KDM4EGSK3ACDK9
SCHEMBL23753421 0.72 USP30 (0.43) ALDH1A1KDM4ELMNAGBA1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981884-B1 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS AMGEN INC (US) 2012-06-13 EP disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
EP-1981884-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS Amgen, Inc (US) 2008-10-22 EP disclosed
WO-2007084391-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS AMGEN INC. (US) 2007-07-26 WO disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270445-A1 Thiazole compounds and methods of use MTOR, JAK2, TK2 NCEH1 1619/4885ABL1 108/4885ALDH1A1 2019/4885
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 NCEH1 1084/4885ABL1 325/4885ALDH1A1 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.